Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial
14/09/2026 13:36
Scholar Rock prices first drug to target SMA muscle loss at $11,659 per vial Sept 14 (Reuters) - Scholar Rock SRRK.O on Monday set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy that directly targets muscle loss in patients with the rare genetic disorder.
The net annual cost for a typical patient will be $310,000, but will vary depending on weight, the company's executives said on a conference call.
(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
((Sriparna.Roy@thomsonreuters.com ; On X as @Sripootweets))
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up